US market entry Immunovia plans to launch PancreaSure in the United States in the second half of 2025, signaling a focused market expansion opportunity for US healthcare providers, distributors, and surveillance programs targeting pancreatic cancer.

LDT pathway Recent news notes PancreaSure launching as an LDT-type test within targeted pancreatic surveillance program centers in the US, suggesting partnerships with clinical sites, data-sharing potential, and potential reimbursement strategy considerations.

Clinical leadership moves Leadership changes in Immunovia’s US operations, including CFO transition and new clinical laboratory leadership, indicate a period of strategic realignment that could affect budgeting cycles, procurement timelines, and vendor onboarding.

US footprint growth The company’s US-based clinical lab presence and relocations to North Carolina (RTP) underscore a growing domestic footprint, offering near-term collaboration opportunities with regional hospital systems, cancer centers, and diagnostic distributors.

Early-stage focus With PancreaSure aimed at Stage 1-2 pancreatic cancer detection, there is a sales opening with high-risk screening programs, gastroenterology practices, and surveillance cohorts seeking accurate, minimally invasive diagnostic options.